performance status


Also found in: Dictionary, Thesaurus, Legal, Acronyms, Encyclopedia, Wikipedia.

status

 [sta´tus, stat´us] (L.)
state, particularly in reference to a morbid condition.
absence status sustained clouding of consciousness for several hours, with no interval of normal mental activity, and with few stereotyped movements or no abnormal motor activity.
status asthma´ticus a particularly severe episode of asthma that does not respond adequately to ordinary therapeutic measures and usually requires hospitalization.
status epilep´ticus rapid succession of epileptic spasms without intervals of consciousness; brain damage may result.
status lympha´ticus lymphatism.
performance status ability of a patient to function, as measured by a performance scale.
status thymicolympha´ticus a condition resembling lymphatism, with enlargement of lymphadenoid tissue and of the thymus as the special influencing factor; formerly thought to be the cause of sudden death in children.
status verruco´sus a wartlike appearance of the cerebral cortex, produced by disorderly arrangement of the neuroblasts, so that the formation of fissures and sulci is irregular and unpredictable.
status (omaha) in the omaha system, the condition of the client in relation to objective and subjective defining characteristics.

performance status

a measure of a patient's well-being defined as the amount of normal activity the patient can maintain.

performance status

A measure of the overall health and functional capability of a patient.
See also: status
References in periodicals archive ?
Performance status score: Do patients and their oncologists agree?
Karnofsky Performance Status Karnofsky Performance Status 3 Weekly Weekly 70 0.5% 1% 80 7% 17% 90 92% 80% 100 0.5% 2% Table 3.
The presence of delirium was directly associated with the ECOG score ([chi square] = 24.28, df = 4, p < .001) and indirectly associated with the Karnofsky Performance Status ([chi square] = 43.75, df = 9, p < .001).
Treatment with nivolumab was associated with a partial radiological response as per RECIST v1.1 along with an improvement in pain control and performance status. Although the median duration of nivolumab treatment in the CheckMate-025 trial was 5.5 months, it is interesting to note that, despite the above-mentioned comorbidities, our patient has been on nivolumab treatment for 22 months with ongoing treatment response.
According to the results of the IMPACT study and the subsequent analyses [28], we confirm that in a population of metastatic pancreatic cancer patients treated with gemcitabine and nab-paclitaxel, Karnofsky performance status score, the presence of liver metastases, and baseline NLR were independent predictors of survival associated with an increased risk of death.
Patients with histologically confirmed common malignancies., adult patients between 20-75 years of age and ECOG performance status of <2 were included in the study while patients with documented or suspected bone marrow infiltration by malignant cells, serious co morbid conditions, such as chronic renal failure or chronic liver disease or cardiac problems, patients who had received high dose chemotherapy followed by bone marrow transplant, patients on concurrent chemo-radiation, patients who had previously received chemotherapy and patients with an active infection or receipt of an antibiotic in the 72 hrs before chemotherapy were excluded from the study.
Patients with liver dysfunction had no relationship with HBV replication or lymphomatous hepatic infiltration but were significantly associated with advanced Ann Arbor stage (p < 0.001), poor performance status (p <0.001), increased LDH level (p < 0.001), high IPI score (p < 0.001), presence of B symptoms (p = 0.002), and low CR rate (p = 0.004, Table 1).
The association remained nominally significant after adjustment for histological type, weight loss, and performance status (HR=0.62, 95% CI = 0.430.92, p = 0.016).
Gastric cancer has a better prognosis than pancreatic cancer, and patients typically have good performance status.[sup][15],[23] The conclusions from existing studies are therefore not entirely appropriate for extrapolation to patients with gastric cancer.
It's more informative than a clinician-assigned ECOG performance status, and including baseline health-related quality of life together with clinical prognostic factors improved the prediction of survival in women with PRR-ROC," Dr.
HIV-positive patients were also more likely to have a poor performance status (ECOG 3 and 4) at presentation (47.7% v.

Full browser ?